Albert David Limited (ALBERTDAVD)
₹831.00 +5.10% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Albert David's revenue was ₹101 Cr (+42.3% year on year, +17.4% on the previous quarter), and net profit ₹32.0 Cr (+300.0% year on year); the operating margin was 10.9%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹101 | +42.3% | +17.4% |
| Operating profit | ₹11.0 | from loss | +266.7% |
| Net profit | ₹32.0 | +300.0% | from loss |
| EPS (₹) | 56.07 | +303.1% | from loss |
| Operating margin | 10.9% | — | — |
ALBERTDAVD delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 79.13% of the ALBERTDAVD shares traded on NSE were taken to delivery, against the stock's own 20-session average of 69.37%. That is higher than usual for this stock. Turnover was only ₹34 lakh, so a handful of trades can move this figure.
Delivery in the last 5 sessions: 78.8% · 72.4% · 55.2% · 59.8% · 79.1%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Albert David Limited has submitted the official minutes of its 87th Annual General Meeting (AGM) to the stock exchanges. The AGM took place on August 6, 2026, at 09:30 a.m. IST through Video Conferencing/Other Audio Visual Means. This is a standard post-AGM regulatory compliance filing with no new operational or financial disclosures provided in the cover letter.
- Submission of minutes for the 87th Annual General Meeting
- AGM was conducted on August 6, 2026, starting at 09:30 a.m. IST
- Meeting was held virtually via Video Conferencing / Other Audio Visual Means (VC/OAVM)
- Filing submitted in compliance with MCA and SEBI LODR regulations on August 29, 2026
Albert David Limited's shareholders approved all seven resolutions at the 87th AGM held on August 6, 2026. Key outcomes include the declaration of a ₹5.00 per share dividend for FY26 and the formal appointment of Mr. Amit Mahla as CEO and Whole-time Director for a five-year term. The company also ratified a revision in remuneration for the Executive Chairman, Mr. Arun Kumar Kothari, for FY27. Voting participation was consistent, with approximately 64.61% of the total 57.07 lakh issued shares represented in the poll.
- Approved a dividend of ₹5.00 per equity share of ₹10 face value for the financial year ended March 31, 2026.
- Appointed Mr. Amit Mahla as Whole-time Director and CEO for a 5-year term from June 19, 2026, to June 18, 2031.
- Ratified the remuneration of Cost Auditors for FY27 at ₹70,000 plus applicable taxes.
- Total votes polled for the adoption of FY26 financials stood at 36,87,639, representing 64.61% of issued shares.
- Approved the re-appointment of Mrs. Prabhawati Devi Kothari as a Director following her retirement by rotation.
Albert David Limited concluded its 87th Annual General Meeting on August 6, 2026, where shareholders approved a dividend of ₹5 per equity share for FY26. A significant leadership transition was formalized with the appointment of Mr. Amit Mahla as Whole-time Director & CEO for a five-year term ending June 2031. Additionally, shareholders voted on the revision of remuneration for Executive Chairman Mr. Arun Kumar Kothari and the ratification of cost auditors for FY27. The meeting also adopted the audited financial statements for the year ended March 31, 2026.
- Approved a dividend of ₹5 per equity share of ₹10 face value for FY26
- Appointed Mr. Amit Mahla as Whole-time Director & CEO for a 5-year term from June 19, 2026, to June 18, 2031
- Revised remuneration for Executive Chairman Mr. Arun Kumar Kothari for the period April 1, 2026, to March 31, 2027
- Established July 30, 2026, as the cut-off date for shareholder voting eligibility
- Adopted audited financial statements and reports for the fiscal year ended March 31, 2026
Albert David Limited has announced the resignation of Dr. Kuntal Ganguly, the Head of Research & Development (R&D), effective from the close of business on August 5, 2026. The resignation is attributed to personal reasons. This departure is notable as the company's qualitative strategy emphasizes R&D focus on new molecules and drug delivery systems to drive future growth. No immediate successor has been named in the filing.
- Dr. Kuntal Ganguly resigned from the position of Head-R&D effective August 5, 2026
- The resignation was submitted due to personal reasons as per the official disclosure
- Company strategy relies on R&D for new molecules to mitigate product concentration risk in placenta-based drugs
- Albert David maintains a net worth of Rs 392 Cr with a relatively low debt of Rs 30 Cr
Albert David Limited has released its unaudited financial results for the quarter ended June 30, 2026. The board meeting, held on August 6, 2026, lasted approximately 3 hours and 40 minutes. The company maintains a conservative capital structure with a debt of Rs 30 Cr against a net worth of Rs 392 Cr (D/E ratio of 0.08). Investors should monitor the detailed P&L for improvements in ROCE, which was recently reported at a low 1.0%.
- Board meeting conducted on August 6, 2026, from 11:35 A.M. to 3:15 P.M.
- Unaudited financial results submitted for the quarter ended June 30, 2026.
- Company debt stands at Rs 30 Cr against a net worth of Rs 392 Cr.
- Promoter holding remains stable at 62.24% as of the June 2026 quarter.
- Company is targeting a 9.80% growth rate through facility upgrades to Revised Schedule-M standards.
Albert David Limited has announced its 87th Annual General Meeting (AGM) is scheduled for August 6, 2026, to be held via video conferencing. The company has completed the dispatch of 1,116 physical letters to shareholders who do not have registered email addresses, providing them with the web-link to the FY 2025-26 Annual Report. The communication also includes details regarding Tax Deducted at Source (TDS) on dividends for the financial year 2025-26. This filing is a standard procedural compliance under SEBI Listing Regulations.
- 87th Annual General Meeting scheduled for August 6, 2026, at 9:30 AM.
- 1,116 physical letters dispatched to shareholders without registered email IDs.
- Notice of the AGM is dated June 19, 2026.
- Communication includes a specific link for TDS details on FY 2025-26 dividends.
Albert David Limited has announced its 87th Annual General Meeting (AGM) for August 6, 2026, to be conducted via video conferencing. The company is highlighting its strategic shift towards R&D, with spending increasing from ₹1.95 Cr to ₹2.89 Cr between FY21 and FY25. Operations are currently focused on upgrading manufacturing units to Revised Schedule-M standards to facilitate global expansion. Shareholders as of the July 30, 2026 cut-off date will be eligible to vote on upcoming resolutions.
- 87th Annual General Meeting scheduled for August 6, 2026, at 09:30 AM IST
- R&D expenditure increased from ₹1.95 Cr to ₹2.89 Cr over the FY21-FY25 period
- Company maintains a distribution network of approximately 2,500 stockists across India
- Debt remains low at ₹30 Cr against a Net Worth of ₹392 Cr (D/E ratio of 0.08)
- Cut-off date for determining e-voting eligibility is fixed for July 30, 2026
Albert David Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Maheshwari Datamatics Pvt. Ltd., covers the period from April 1, 2026, to June 30, 2026. It confirms that share certificates received for dematerialization were processed and the physical certificates were mutilated or cancelled as per regulations. This is a standard administrative filing to ensure the integrity of the company's shareholding records.
- Compliance certificate covers the quarter ended June 30, 2026.
- Registrar Maheshwari Datamatics Pvt. Ltd. confirmed processing of demat requests within stipulated timelines.
- Physical security certificates were destroyed/mutilated after dematerialization as per SEBI norms.
- The filing confirms the alignment of share records between the company and depositories (NSDL/CDSL).
Albert David Limited has announced the resignation of Mr. Saikath Banerjee, who served as the Cluster-Head, effective July 4, 2026. The departure is attributed to personal reasons, and the company has formally acknowledged his contributions. Given the company's quarterly revenue scale of approximately ‡98.4 cr (Sep 2024), the exit of a cluster-level executive is an operational change rather than a strategic shift. No immediate successor has been named in the filing.
- Mr. Saikath Banerjee resigned from the position of Cluster-Head effective July 4, 2026.
- The resignation was tendered due to personal reasons as per the Annexure-A filing.
- Company reported a TTM revenue base supported by a Sep 2024 quarterly revenue of ‡98.43 cr.
- The company maintains a promoter holding of 62.23% as of the latest reporting period.
CARE EDGE Ratings has reaffirmed Albert David Limited's long-term rating at 'CARE A' and short-term rating at 'CARE A1'. The outlook for the long-term facilities remains 'Negative', indicating potential risks to the company's credit profile or financial performance. The total rated bank facilities have been slightly reduced to ₹62.50 crore from the previous ₹64.50 crore. This review follows the assessment of the company's financial performance for the fiscal year 2026.
- Long-term bank facilities of ₹50.50 crore reaffirmed at 'CARE A' with a 'Negative' outlook.
- Short-term bank facilities of ₹12.00 crore reaffirmed at 'CARE A1'.
- Total rated bank facilities decreased by ₹2.00 crore, from ₹64.50 crore to ₹62.50 crore.
- Rating review was based on the company's operational and financial performance for FY26.
Albert David Limited has announced that its trading window will be closed starting July 1, 2026, for the purpose of declaring Unaudited Financial Results for the quarter ending June 30, 2026. The company will implement PAN freezing for all designated persons and their immediate relatives through CDSL to ensure compliance with SEBI Insider Trading regulations. The trading window is scheduled to reopen 48 hours after the financial results are made public. The specific date for the board meeting to approve these results will be announced at a later time.
- Trading window closure begins on Wednesday, July 1, 2026.
- Closure pertains to the Unaudited Financial Results for the quarter ended June 30, 2026.
- PAN freezing for designated persons will be executed via CDSL as per SEBI circulars.
- Trading window will reopen 48 hours after the official declaration of financial results.
Albert David Limited has officially appointed Mr. Amit Mahla as an Additional Director and Whole-time Director & CEO for a five-year tenure effective June 19, 2026. Mr. Mahla, who has served as the company's CEO since May 12, 2026, brings over 28 years of experience from major pharmaceutical firms including Cipla, Sun Pharma, and JB Pharma. The appointment and his remuneration for the period ending March 31, 2027, are subject to shareholder approval at the upcoming 87th Annual General Meeting. This move is aimed at leveraging his expertise in business transformation and strategic leadership within the Indian Pharmaceutical Market.
- Appointment of Mr. Amit Mahla as Whole-time Director & CEO for a 5-year term from June 19, 2026, to June 18, 2031.
- Mr. Mahla possesses over 28 years of industry experience with leadership roles at Cipla, Sun Pharma, and JB Pharma.
- The Board has revised the 87th AGM notice to include shareholder approval for this appointment and remuneration fixation.
- The appointee previously led the integration of Sanzyme into JB Pharma, demonstrating high-level M&A and integration expertise.
- Remuneration for the initial period from June 19, 2026, to March 31, 2027, has been approved by the Board.
Albert David Limited has officially appointed Mr. Amit Mahla as an Additional Director and Whole-time Director & CEO for a five-year tenure starting June 19, 2026. Mr. Mahla, who has been serving as CEO since May 12, 2026, brings over 28 years of industry experience from major firms like Sun Pharma, Cipla, and JB Pharma. The appointment is subject to shareholder approval at the upcoming 87th Annual General Meeting. This move aims to leverage his expertise in business transformation and strategic leadership within the Indian Pharmaceutical Market.
- Appointment of Amit Mahla as Whole-time Director & CEO for a 5-year term ending June 18, 2031.
- Mr. Mahla possesses over 28 years of experience in the pharmaceutical sector with a track record of building 20+ major brands.
- Previous leadership experience includes roles at top-tier companies such as Sun Pharma, Glenmark, and JB Pharma.
- The Board has revised the 87th AGM notice to include shareholder approval for his appointment and remuneration.
- Mr. Mahla is recognized for leading the integration of Sanzyme into JB Pharma, a major recent acquisition in the industry.
Albert David Limited has elevated its CEO, Mr. Amit Mahla, to the position of Whole-time Director & CEO for a five-year tenure effective June 19, 2026, to June 18, 2031. Mr. Mahla, who joined the company as CEO in May 2026, brings over 28 years of experience from major pharmaceutical firms including Sun Pharma, Cipla, and JB Pharma. The Board has also fixed his remuneration through March 31, 2027, and revised the 87th AGM notice to seek shareholder approval for these appointments. This leadership move is intended to drive business transformation and strategic growth.
- Mr. Amit Mahla appointed as Whole-time Director & CEO for a 5-year term ending June 18, 2031.
- The appointee has over 28 years of experience in the Indian Pharmaceutical Market, with prior leadership roles at JB Pharma and Sun Pharma.
- Remuneration for the period June 19, 2026, to March 31, 2027, has been approved by the Board.
- The 87th AGM notice has been revised to include shareholder approval for the regularization of this appointment.
- Mr. Mahla is recognized for brand building and successfully leading the Sanzyme integration into JB Pharma.
Albert David Limited has announced the resignation of Mr. Chandra Bhushan Thakur, who served as the Head of Operations for the company's Ghaziabad manufacturing unit. The resignation became effective from the close of business hours on May 29, 2026. The company cited personal reasons for his departure and expressed appreciation for his contributions during his tenure. As this involves a senior managerial position at a key plant, it is a routine but necessary disclosure for transparency.
- Mr. Chandra Bhushan Thakur resigned as Head-Operations of the Ghaziabad Plant.
- The resignation was effective as of May 29, 2026.
- The departure is attributed to personal reasons according to the regulatory filing.
- The company has acknowledged his service and contributions during his tenure.
Financial Performance
Revenue Growth by Segment
The company operates in a single pharmaceutical segment. Total revenue from operations for FY25 was INR 345.76 Cr, representing a decline of 4.61% compared to INR 362.46 Cr in FY24.
Geographic Revenue Split
Not disclosed in available documents as the company operates in a single segment and does not segregate by geographical presence.
Profitability Margins
Profitability saw a significant decline in FY25. Operating Profit Margin turned negative at -3.61% from 4.95% in FY24. Net Profit Margin dropped to 5.01% from 20.93% YoY. Return on Net Worth decreased by 18.86 percentage points to 6.27% from 25.13%.
EBITDA Margin
EBITDA margin for FY25 was 9.43% (INR 32.61 Cr), a sharp decline of 68.77% from INR 104.43 Cr (28.81% margin) in FY24 due to increased employee and distribution expenses.
Capital Expenditure
Historical capital expenditure for the half-year ended September 30, 2025, was INR 6.28 Cr, primarily for upgrading facilities as per Revised Schedule-M.
Credit Rating & Borrowing
CARE A; Negative (Outlook revised from Stable in June 2025). Borrowings increased to INR 39.52 Cr as of September 2025 from INR 10.05 Cr in March 2025, leading to a 366.97% increase in the Debt-Equity ratio to 0.03.
Operational Drivers
Capacity Expansion
The company is currently upgrading its manufacturing units to comply with Revised Schedule-M standards to meet market demand and improve cost control.
Manufacturing Efficiency
Efforts are being made to adopt the latest technology to upgrade units for effective cost control; however, specific utilization percentages were not disclosed.
Logistics & Distribution
Sales and distribution costs increased significantly in FY25 as part of a strategy to expand market reach and product penetration.
Strategic Growth
Expected Growth Rate
9.80%
Growth Strategy
Growth is targeted through upgrading facilities to Revised Schedule-M standards, R&D focus on new molecules and drug delivery systems, and increased spending on sales and distribution to penetrate new markets.
Products & Services
Placenta-based drugs and other pharmaceutical formulations.
Brand Portfolio
Albert David.
New Products/Services
R&D team is working on new molecules to strengthen the product pipeline; expected revenue contribution was not disclosed.
Market Expansion
The company is expanding its market reach through higher sales and distribution costs, though specific target regions were not named.
Market Share & Ranking
The company holds an established market position in placenta-based drugs.
External Factors
Industry Trends
The pharmaceutical industry is highly challenging with a focus on quality and drug delivery systems. The industry is evolving towards stricter manufacturing standards like Revised Schedule-M.
Competitive Landscape
The company operates in a highly challenging pharmaceutical market with moderate scale of operations compared to larger peers.
Competitive Moat
The moat is built on an established market position in placenta-based drugs and a strong distribution network, which are sustainable due to the specialized nature of these products.
Macro Economic Sensitivity
The company is sensitive to GDP growth, with the sector growth estimated at 9.8% and Real GVA growth at 6.4% for FY25.
Geopolitical Risks
Subject to unforeseen predicaments in government policies and local political/economic developments.
Regulatory & Governance
Industry Regulations
Compliance with Revised Schedule-M of the Drugs and Cosmetics Act is a critical manufacturing standard currently being implemented.
Taxation Policy Impact
Current tax for the half-year ended September 30, 2025, was INR 3.21 Cr.
Risk Analysis
Key Uncertainties
Significant decline in profitability margins (PAT down 77.19%) and anticipated continuation of subdued financial performance in upcoming quarters.
Technology Obsolescence Risk
The company mitigates technology risk by keeping track of latest developments and maintaining touch with foreign machine suppliers.
Credit & Counterparty Risk
Debtors Turnover Ratio remained stable at 12.11 times in FY25 compared to 12.08 times in FY24, indicating consistent receivables quality.
